로딩 중…
지수 로딩 중…
L&C BIO Co.,LTD
290650· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩58,700+20.91%
2026-08-04
Financials
Valuation Metrics
L&C BIO Co.,LTD's Market Cap is ₩1.6T. At end of 2025 it was ₩1.6T. Ranked #234 of 2,436 in KR market (top 10%), #51 of 1,649 on KOSDAQ (top 3%), #23 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 10%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.58T KRW | KR#234/2,436 Sec#23/234 |
| Revenue | 98.01B KRW | KR#1,406/2,436 Sec#88/234 |
| Net Income | -134.88B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 467.09B KRW | KR#775/2,436 Sec#46/234 |
| Net Assets | 213.22B KRW | KR#889/2,436 Sec#63/234 |
| Employees | 135 | KR#1,397/2,436 Sec#113/234 |
| Value | ||
| P/B | 7.42x | KR#2,304/2,436 Sec#199/234 |
| P/S | 16.15x | KR#2,319/2,436 Sec#178/234 |
| EV/EBITDA | 149.96x | KR#1,503/2,436 Sec#105/234 |
| FCF Yield | -0.20% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -63.26% | KR#2,298/2,436 Sec#208/234 |
| ROA | -28.88% | KR#2,290/2,436 Sec#194/234 |
| Op. Margin | 11.07% | KR#433/2,436 Sec#40/234 |
| Revenue Growth | 70.61% | KR#199/2,436 Sec#23/234 |
| Earnings Growth | -196.26% | KR#1,493/2,436 Sec#97/234 |
| Financial Health | ||
| Debt Ratio | 119.07% | KR#634/2,436 Sec#79/234 |
| Total Debt | 87.49B KRW | KR#764/2,436 Sec#50/234 |
| FCF | -3.25B KRW | KR#1,409/2,436 Sec#110/234 |
| Cash | 43.85B KRW | KR#812/2,436 Sec#51/234 |
| Current Ratio | 0.64x | KR#2,172/2,436 Sec#207/234 |
| Net Debt/EBITDA | 4.02x | KR#1,024/2,436 Sec#77/234 |
| Dividend | ||
| Div. Yield | 0.10% | KR#1,373/2,436 Sec#88/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | 86.94% | KR#145/2,436 Sec#16/234 |
| 1M Return | -29.36% | KR#2,353/2,436 Sec#230/234 |
| From 52W High | -53.04% | KR#1,343/2,436 Sec#113/234 |
| 1Y MDD | -58.96% | KR#1,348/2,436 Sec#108/234 |
| Trading | ||
| Volume | 489,895 shares | KR#279/2,436 Sec#31/234 |
| Foreign Own. | 22.16% | KR#184/2,436 Sec#8/234 |
| Per Share | ||
| EPS | -5,531 KRW | KR—/2,436 Sec—/234 |
| BPS | 8,240 KRW | KR#1,061/2,436 Sec#75/234 |
Company Info
동사는 2011년 설립된 조직공학 치료재료 전문 바이오 기업으로, 2018년 코스닥시장에 상장하였음. 연결대상 종속회사로 GMRC 등 4개사를 보유하고 있으며, 당분기 중 엘앤씨에이아이와 엘앤씨퓨처랩의 지분을 매각하였음. 동사는 인체조직이식재, 의료기기, 코스메슈티컬 제조·판매와 제약사업, 자회사 GMRC를 통한 기능성 화장품·건강기능식품 CRO사업, AI 화장품 추천 플랫폼 사업을 영위하고 있음. 엘앤씨바이오는 2011년에 설립되었으며 경기도 성남시에 본사를 두고 있습니다.